NXAQ
LIVE

Serial Number

99816392

Owner

Nxera Pharma Co., Ltd.

Attorney

Eric Lamb

Filing Date

May 11, 2026

Add to watchlist:

No watchlists yet
View on USPTO

NXAQ Trademark

Serial Number: 99816392

NXAQ is a trademark filed by Nxera Pharma Co., Ltd. on May 11, 2026. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Nxera Pharma Co., Ltd. (3 trademarks)

Midtown East 9-7-2 Akasaka Minato-ku
Tokyo 107-0052 , JP

Entity Type: 99

Trademark Details

Filing Date

May 11, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceutical services; pharmaceutical advice and consultancy for medical purposes; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; research, creation, development and provision of chemical and biological drug targets for medical screening purposes; all of the aforesaid relating to drug discovery and use of G-protein-coupled receptors in the design and development of pharmaceutical products

Business management, organisation and administration in the field of chemical products, biological products, pharmaceuticals, design and development of drugs, drug discovery; business management, organisation and administration in the field of research and development services in the pharmaceutical and biopharmaceutical fields, including technologies related to proteins and G-protein-coupled receptors; retail and wholesale services connected with the sale of pharmaceuticals, biological products and chemical and biological preparations; database management; computer database management; collection and compilation of data; compilation and systemisation of information and data in computer databases; compilation of information and data relating to life sciences, chemical and biological drug discovery, target identification, lead identification, pharmaceuticals, design and development of drugs, diagnostics and therapeutics; data processing, systemisation and management; data processing services; providing business statistical information for use in predictive analytics and predictive modelling via computer databases; information, advisory and consultancy services relating to all of the aforesaid services

Drug and pharmaceutical discovery services; bio-technology, pharmaceutical, chemical and medical testing, research, development, advice, consultancy and information services; research and development services in the pharmaceutical and biopharmaceutical fields, including technologies related to proteins and G-protein-coupled receptors; pharmaceutical research services in chemical and biological drug discovery and development; research and development services for identifying lead chemical compounds; examination and research services in medicinal and synthetic chemistry; research and development services in the creation of libraries or collections of biologicals, chemicals and compounds; research, creation, development and provision of chemical and biological drug targets for screening purposes; research, analysis and examination for identification of compounds through automated screening processes; research and development services in chemical and biological pharmaceutical development; medical laboratory services; artificial intelligence as a service [AIaaS], software as a service, platform as a service [PaaS]; design and development of computer software; providing online non-downloadable computer software; providing online non-downloadable computer software for searching, tracking, modelling, exploration and analysis of data; computer programming; compilation of scientific information; preparation of scientific and technological reports; provision of scientific and technical information and data; information, advisory and consultancy services relating to all of the aforesaid services; all of the aforementioned being in the field of life sciences, chemical and biological drug discovery, molecular simulation, target identification, lead identification, pharmaceuticals, design and development of drugs, diagnostics and therapeutics

Software, application software, computer software, computer software platforms, artificial intelligence, generative artificial intelligence software, generative design software, deep learning software, neural networks software and machine learning software, large language models software, frontier models software, foundation models software, retrieval augmented generation trained models software, knowledge graphs software; computer software for accessing, browsing and searching online databases; computer software for searching, tracking, modelling, exploration and analysis of data; artificial intelligence software for searching, tracking, modelling, exploration and analysis of data; databases; computer databases; data banks; electronic databases; interactive databases; data processing software; all of the aforementioned being in the field of life sciences, chemical and biological drug discovery, molecular simulation, target identification, lead identification, pharmaceuticals, design and development of drugs, diagnostics and therapeutics

Filing History

APPLICATION FILING RECEIPT MAILED
May 11, 2026 MAFR
NEW APPLICATION ENTERED
May 11, 2026 NWAP